“`html
FDA Fast-Tracks Novel Cholesterol drug & Lung Cancer Therapy with Priority Vouchers
Table of Contents
The Food and Drug Management (FDA) has granted two national priority vouchers to Merck & Co. for its investigational therapies enlicitide decanoate and sacituzumab tirumotecan (sac-TMT), signaling an anticipated acceleration in their review and potential approval. This move underscores the agency’s commitment to addressing critical healthcare needs and improving access to innovative treatments.
The vouchers, awarded under the Commissioner’s National priority Voucher (CNPV) pilot program, are designed to incentivize the development of products tackling significant public health challenges. Established in June 2025, the program has now awarded 18 vouchers to date. “high health care costs and prescription drug prices threaten to undermine all the technological advancements we see in the medical field,” stated a senior official in a recent agency release. “We’re pleased to grant these vouchers to 2 products that may significantly contribute to our goal of improving the accessibility and affordability of health care in America.”
Implications for Pharmacists: Anticipating Faster Approvals
The FDA’s utilization of national priority vouchers indicates an expedited review process for these high-impact therapies, prompting pharmacists to prepare for perhaps quicker market availability and the need to update formularies and clinical guidelines.
Enlicitide Decanoate: A New Approach to Lowering Cholesterol
Enlicitide decanoate,a novel oral medication,has demonstrated significant efficacy in reducing LDL-C levels,a key factor in cardiovascular disease. The VICTORION-2 trial (NCT05789317) showcased a 55.2% reduction in LDL-C at week 24 in patients with hypercholesterolemia (95% CI, -60.3 to -49.9, P < .001).These benefits were sustained, with a 47.6% reduction in LDL-C observed at the one-year mark (95% CI, -52.7 to -42.5, P < .001).
The CORALreef HeFH trial (NCT05952869) focused on patients with heterozygous familial hypercholesterolemia (HeFH), a genetic condition leading to abnormally high LDL-C levels. Patients treated with enlicitide decanoate experienced a 59.4% reduction in LDL-C at week 24 compared to placebo (95% CI, -65.6 to -52.2, P <.001), alongside positive effects on non-HDL-C, ApoB, and Lp[a].Notably, LDL-C reductions were observed as early as week 4, with a 61.5% reduction at one year (95% CI, -69.4 to -53.7, P < .001).
These findings suggest that enlicitide decanoate, as a once-daily oral pill, has the potential to revolutionize cholesterol management for millions.
Sacituzumab tirumotecan: New Hope for Advanced NSCLC
The voucher awarded to sac-TMT highlights a promising new treatment option for patients with EGFR-mutated non-small cell lung cancer (NSCLC). Sac-TMT is a trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate, currently under investigation for individuals with previously treated advanced or metastatic NSCLC harboring EGFR mutations.
The OptiTROP-Lung04 clinical trial (NCT05870319) demonstrated the effectiveness and safety of sac-TMT in patients whose NSCLC had progressed after prior EGFR-tyrosine kinase inhibitor therapy. The trial, which randomized 376 patients, revealed a median progression-free survival (PFS) of 8.3 months with sac-TMT, compared to 4.3 months with platinum-based chemotherapy (hazard ratio [HR] for disease progression or death, 0.49; 95% CI, 0.39 to 0.62) at a median follow-up of 18.9 months. Overall survival (OS) was also significantly longer with sac-TMT (HR, 0.60; 95% CI, 0.44 to 0.82; P = .001).
Having already received breakthrough therapy designation, sac-TMT’s pathway to approval is now further bolstered by the national priority voucher. if approved, this drug could address a significant unmet need for patients with advanced or metastatic NSCLC with EGFR mutations, a population with limited treatment options.
The FDA
